Be part of our community by subscribing to our newsletters! Follow the steps below.

1. Subscribe to our Announcement Newsletter. You will receive our news about what do you need to know about our work and the resources available for you. You need to confirm your subscription by email (check your email box and confirm your subscription)

2. Choose your favorite writer. We constantly look for the top minds on the pharmaceutical marketing industry. You can subscribe to their article on their pages and receive every article on your inbox. 

3. Choose the Newsletter that better fits you needs. We recommend the Editor’s pick to receive everything you need to know in one weekly email. 

4. All our newsletters needs to be confirmed by email. After you subscribe on our webpage, you will receive an email asking for your confirmation by clicking a link. Click that link if you want to receive the newsletter. If you don’t receive the email, check your spam box and add our email to your safe sender list. If you address belongs to a company, you may need to forward your confirmation email to your tech department to ask them to add our domain to your company safe sender list. 

You can start here by subscribing to our main Newsletter. Confirm your subscription by clicking CONFIRM on the email you will receive after complete the subscription form.

Don’t forget to check for our other newsletters! Check this page for several options we have for all our users!

NEWSLETTER ANNOUCEMENTS

TPMG FEATURED WRITER NEWSLETTER

- Advertisement -

Top 10 things to consider when designing hybrid meetings

Although the Omicron variant of COVID-19 might have set back the full return to in-person meetings for now, there is no doubt that the future is hybrid. At Impetus Digital, we are slowly seeing more people inquire about our hybrid offerings and how to combine our virtual tools with...

Importance of Diversity in Pharma and Clinical Trials

A version of this article was previously published on PharmaPhorum. “Diversity.” It’s a word that is very commonly thrown around right now, not just in Pharma and healthcare but across all industries. No matter which sector you work in, diversity and inclusion should not be treated as mere buzzwords designed...

Virtual collaboration tools to reduce “digital overload”

A version of this article was previously published in the Journal of mHealth. The COVID-19 pandemic has substantially altered the ways we work, connect with family and friends, and attend meetings and events. By now, “Zoom fatigue”–i.e., tiredness, anxiety, or worry resulting from overusing Zoom and other synchronous virtual platforms–and “digital...

Digital technologies: Pharma’s answer to achieving net zero emissions?

A version of this article was previously published in the Journal of mHealth. As I wrote about earlier this year, it is clear that the climate crisis is no longer something for future generations to worry about, it’s already here and requires our urgent and undivided attention. The Pacific Northwest...

Natalie Yeadon´s Newsletter

- Advertisement -

Digital Opinion Leaders (DOLs): Who are they and how...

A version of this article was previously published in the Journal of mHealth. With our growing dependence on social media over the past decade, Digital Opinion Leaders–or “DOLs” for short–are becoming an increasingly important stakeholder group for Pharma teams to engage and consult. But who are these DOLs, and why...

Impetus Digital Green Team named PM360 ELITE Environmental Champions

Press Release Contact: Cecilia Petrus, Communications Director / Green Team Leader cpetrus@impetusdigital.com www.impetusdigital.com IMPETUS DIGITAL GREEN TEAM NAMED ONE OF THE 2022 PM360 ELITE 100 Toronto, ON, May 17, 2022 — PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, has named the Impetus Digital Green...

Top 10 things to consider when designing hybrid meetings

Although the Omicron variant of COVID-19 might have set back the full return to in-person meetings for now, there is no doubt that the future is hybrid. At Impetus Digital, we are slowly seeing more people inquire about our hybrid offerings and how to combine our virtual tools with...

Importance of Diversity in Pharma and Clinical Trials

A version of this article was previously published on PharmaPhorum. “Diversity.” It’s a word that is very commonly thrown around right now, not just in Pharma and healthcare but across all industries. No matter which sector you work in, diversity and inclusion should not be treated as mere buzzwords designed...

EDITOR´S PICK

- Advertisement -

Ipsen to acquire Epizyme, expanding its portfolio in oncology

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by...

The Lancet Publication Shows Benefits of PharmaJet Needle-free delivery...

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that the phase 3 clinical study sponsored by their partner, Zydus Lifesciences, has been published in The Lancet. The peer-reviewed article, entitled Efficacy,...

United Therapeutics Provides an Update on Its Organ Printing...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & ROCK HILL, S.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that in partnership with 3D Systems Corporation (NYSE: DDD) it has produced the world’s most complex 3D-printed object – a human lung scaffold – and demonstrated...

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Saira Ramasastry to the Company’s board of directors and as a member of the audit committee where she will bring to bear her more than 20 years of financial leadership. “Saira’s extensive financial and strategic experience will...

LOOK WHO IS ON THE MOVE!

Paul Fry appointed as Argenta’s new Chief Financial Officer

LONDON--(BUSINESS WIRE)--Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately. To ensure a smooth transition, Paul will work closely with former CFO Chris O’Donnell until late August. The CFO role is being relocated from New Zealand to London to enable the...

Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer. Together, these leaders will...

Ambys Medicines Announces Formation of Clinical and Scientific Advisory...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, today announced the formation of its clinical and scientific advisory boards comprising leading clinical experts in liver disease and hepatocyte transplantation, and world-class scientists pioneering cell and gene technologies. The clinical advisory board provides...

Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer. Dr. Moore brings more...

INDUSTRY NEWS

- Advertisement -

Trastuzumab Deruxtecan Recommended for Approval in the EU by...

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) trastuzumab deruxtecan has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens. Trastuzumab...

Transgene and BioInvent Announce Positive Progress for BT-001

STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today...

European Academy of Neurology (EAN 2022) – Braintale to...

STRASBOURG, France--(BUSINESS WIRE)--Braintale, a medtech deciphering white matter, spin off from the Paris Greater Hospitals has presented the results of SOM-ALS sub-study in amyotrophic lateral sclerosis (ALS) during the European Academy of Neurology (EAN 2022) congress both in Vienna (Austria) and digitally from June 25th to 28th, 2022. Long underestimated...

Results from Phase 2 Study of Fazirsiran in Patients...

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD) were recently published in the New England Journal...

REGULATORY AFFAIRS

 US FDA Approves Prestige Biopharma’s IND for Phase 1/2a...

SINGAPORE--(BUSINESS WIRE)--Prestige Biopharma Limited, a Singapore-based biopharmaceutical company with operations in USA and South Korea, announced that the U.S. Food and Drug Administration (FDA) has approved the Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510 (INN: Ulenistamab), for the treatment of pancreatic cancer. The clinical trial will...

Nuvation Bio Announces FDA Partial Clinical Hold for Phase...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s Phase 1 dose escalation study of...

Cybin Receives FDA IND Clearance for its Phase 1/2a...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that it has received a “may proceed letter” and Investigational New Drug Application (“IND”) clearance from the U.S. Food and Drug Administration (“FDA”) for its Phase 1/2a first-in-human...

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and...
Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.